SCHEMBL7799997

SCHEMBL7799997

CCOc1ccc(C(=O)Nc2ccc3c(c2)CN(C)CCC3)cc1C(C)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.60
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALOX15 P16050 1/20 0.51
ALOX12 P18054 1/20 0.51
NR4A1 P22736 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ROCK2 O75116 5/20 0.51
CYP3A4 P08684 1/20 0.51
CREBBP Q92793 2/20 0.50
POLB P06746 3/20 0.48
LMNA P02545 1/20 0.48
KMT2A Q03164 1/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7792020 0.88 MAPT (0.66) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL7802384 0.88 MEN1 (0.58) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL7797951 0.83 ROCK2 (0.51) TP53MAPTSMN1; SMN2ROCK2CYP3A4
SCHEMBL7656209 0.83 MAPT (0.47) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL6293914 0.82 MAPT (0.68) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL6299444 0.82 ROCK2 (0.63) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL6299445 0.81 ROCK2 (0.56) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL6294916 0.80 ROCK2 (0.54) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL7013968 0.79 TP53 (0.51) TP53MAPTSMN1; SMN2ALOX15ALOX12
SCHEMBL6293942 0.78 KMT2A (0.64) TP53MAPTSMN1; SMN2ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A TP53 4518/4885MAPT 353/4885SMN1; SMN2 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.